Drug Profile
Dactolisib - Novartis/Adicet Bio
Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Adicet Bio; Brown University Medical School; Memorial Sloan-Kettering Cancer Center; Novartis
- Class 3-ring heterocyclic compounds; Acetonitriles; Anti-infectives; Antineoplastics; Antiparkinsonians; Antivirals; Benzenesulfonates; Heart failure therapies; Imidazoles; Nitriles; Quinolines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Respiratory tract infections
- Phase II COVID 2019 infections; Influenza virus infections
- Phase I/II Parkinson's disease
- Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Heart failure; Urinary tract infections
- Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Heart-failure(Combination therapy) in USA (PO)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Parkinson's-disease(Combination therapy) in USA (PO, Capsule)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Urinary-tract-infections in USA (PO)